Figma Shares Indicated To Open $105/$110
Cathie Wood’s ARK ETF disclosed their daily trades for Tuesday, April 15th, 2025, revealing a continued interest in technology and healthcare sectors. The most significant transaction for the day involved the purchase of 58,092 shares of GitLab Inc (NASDAQ:GTLB) via the ARKK ETF, amounting to a total value of approximately $2.46 million. This acquisition reflects ARK’s ongoing confidence in the software development platform, which has seen consistent buying activity from the firm.
On the sell side, ARK reduced its holdings in the biotechnology space, offloading 93,908 shares of Repare Therapeutics Inc (NASDAQ:RPTX) through the ARKG ETF, with a total dollar value of around $87,146. This sell-off is part of a broader trend, as ARK has been gradually decreasing its investment in Repare Therapeutics over the past trading sessions.
Additionally, ARK trimmed its position in Prime Medicine Inc (NASDAQ:PRME) by selling 4,087 shares through the ARKK ETF, which equated to a relatively modest $5,435. This follows a pattern of selling in the stock, as seen in previous daily trade reports.
Looking back at the trades since last week, ARK has been actively managing its portfolio across various sectors. Notable transactions include a significant buy of 460,044 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) through the ARKK ETF last Thursday, valued at over $2.64 million, suggesting a bullish stance on the company’s prospects.
Conversely, ARK has consistently sold shares of UiPath Inc (NYSE:PATH), with the largest sale occurring last Tuesday, where ARK divested a total of 1,625,616 shares across its ETFs, amounting to over $15.9 million. This move might indicate a strategic shift or profit-taking by the firm in the automation software company.
Investors following Cathie Wood’s ARK ETFs can observe a dynamic approach to portfolio management, with the firm actively buying and selling positions based on their evolving investment thesis. The focus on innovative and disruptive companies remains a hallmark of ARK’s investment strategy, as they continue to navigate the market landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.